All In Biotech

Drug Trial Radar · NCT03228108

Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

The Effect of Rectal Swab Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy on Infectious Complications and Cost of Care: A Randomized Controlled Trial in the Netherlands.

Last checked: Nov 20, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,538 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,538

Actual

Start

Apr 3, 2018

Primary completion

Sep 26, 2021

Study completion Sep 26, 2021

Sponsor

Lead sponsor
Radboud University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Jul 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to assess the effectiveness and cost-effectiveness of rectal swab culture-guided antimicrobial prophylaxis to reduce infectious complications after transrectal prostate biopsy. Half of participants will receive routine empirical prophylaxis with oral ciprofloxacin (control group), while the other half will receive rectal culture-guided oral antibiotic prophylaxis (intervention group). In the intervention group, men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prophylaxis, comparable to the control group. In case of ciprofloxacin-resistant bacteria an alternative oral antibiotic based on the culture results will be prescribed (trimethoprim/sulfamethoxazole, fosfomycin or pivmecillinam/augmentin). The investigators hypothesise that the targeted prophylaxis group (intervention group) will have a lower rate of post-biopsy infectious complications compared to the control group.

Conditions

  • Complication
  • Infection
  • Prostate Cancer

Interventions

  • CiprofloxacinDrug

    see study arms.

  • Trimethoprim/SulfamethoxazoleDrug

    see study arms.

  • FosfomycinDrug

    see study arms.

  • Pivmecillinam/augmentinDrug

    see study arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Any registered clinical infectious complication after prostate biopsyTime frame: within 7 days post-biopsy

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Jeroen Bosch Hospital

    's-Hertogenbosch, Netherlands

  • Rijnstate

    Arnhem, Netherlands

  • Bravis

    Bergen op Zoom, Netherlands

  • Amphia Hospital

    Breda, Netherlands

  • Catharina Hospital

    Eindhoven, Netherlands

  • Zuyderland Hospital

    Heerlen, Netherlands

  • Canisius Wilhelmina Hospital

    Nijmegen, Netherlands

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • Bravis

    Roosendaal, Netherlands

  • Zuyderland Hospital

    Sittard, Netherlands

  • Elisabeth Tweesteden Hospital

    Tilburg, Netherlands

  • Bernhoven Hospital

    Uden, Netherlands

  • Isala

    Zwolle, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.